Depomed, Inc. Logo

Depomed Announces Receipt of $2.5 Million License Fee From Boehringer Ingelheim

Print
| Source: Depomed, Inc.

MENLO PARK, Calif., March 28, 2012 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) today announced that it has received the remaining license fee payment resulting from its collaboration with Boehringer Ingelheim, a research-driven global pharmaceutical company, headquartered in Ingelheim, Germany. The payment follows the development and delivery of prototype formulations meeting pre-specified attributes under its agreement to license Acuform® technology and data to Boehringer Ingelheim signed in March 2011. Under the terms of the agreement, Depomed has licensed to Boehringer Ingelheim worldwide rights to Depomed's Acuform® gastric retentive drug delivery technology to develop and commercialize certain fixed dose combination products that include extended release metformin and proprietary Boehringer Ingelheim compounds in development for type 2 diabetes. Under the terms of the agreement, Depomed is eligible to receive additional milestone payments based on regulatory filing and approval events and royalties on worldwide net sales of products.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. GraliseTM (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

The Depomed, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7529

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to the efforts of our collaboration partners to commercialize products; our research and development efforts; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. The achievement of those plans and objectives involves risks and uncertainties including, but not limited to, risks and uncertainties related to the timing and outcome of clinical trials, launch and market acceptance of Gralise; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

August J. Moretti
Depomed, Inc.
650-462-5900